Provided by Tiger Trade Technology Pte. Ltd.

Clearmind Medicine, Inc.

6.61
+0.770013.18%
Volume:142.90K
Turnover:886.58K
Market Cap:3.35M
PE:-0.06
High:6.70
Open:5.75
Low:5.54
Close:5.84
52wk High:3,840.00
52wk Low:5.25
Shares:507.40K
Float Shares:507.20K
Volume Ratio:4.00
T/O Rate:28.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-118.4105
EPS(LYR):-2,427.8177
ROE:-106.98%
ROA:-53.08%
PB:0.26
PE(LYR):0.00

Loading ...

Clearmind Medicine submits psychedelic therapy recommendations to FDA

TIPRANKS
·
Yesterday

Clearmind Submits Recommendations to FDA on Future Therapeutic Use of Psychedelic Drugs

Reuters
·
Yesterday

Clearmind Medicine - Calls for Research and Clinical Collaborations with Va, Dow, and Hhs

THOMSON REUTERS
·
Yesterday

Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA

THOMSON REUTERS
·
Yesterday

NASDAQ Trade Halt Continues Reason not Available at 03:58 Am

Reuters
·
Oct 05

NASDAQ Trade Halt Continues Halt News Pending at 03:28 Am

Reuters
·
Oct 03

Clearmind Medicine Inc trading halted, news pending

TIPRANKS
·
Oct 03

Clearmind Medicine: Effects 1-for-8 Reverse Share Split, Effective October 5, 2026

THOMSON REUTERS
·
Oct 01

Clearmind Medicine to Consolidate Shares 1-for-8 Oct. 5 on NASDAQ

Reuters
·
Oct 01

NeuroThera Labs Expands U.S. Patent Portfolio in Collaboration with Clearmind Medicine

Reuters
·
Sep 23

Clearmind Medicine Publishes Three US Patent Applications for LSD, Ketamine, Ibogaine Combinations with PEA

Reuters
·
Sep 23

Clearmind Medicine briefs FDA following psychedelic hearing in Washington D.C.

TIPRANKS
·
Sep 17

Clearmind Briefs FDA Panel at Washington Psychedelic Drugs Hearing

Reuters
·
Sep 17

Clearmind Enrolls First AUD Patients in CMND-100 Clinical Trial

Reuters
·
Sep 11

Clearmind Enrolls First Patients with Alcohol Use Disorder in Cmnd-100 Clinical Trial

THOMSON REUTERS
·
Sep 11

Clearmind Net Loss Narrows to USD 907,291 in Q3 FY26; Cash Climbs to USD 12.04 Million at July 31, 2026

Reuters
·
Sep 11

Clearmind Medicine Wins Yale IRB Clearance to Recruit Patients for CMND-100 Trial Parts B and C

Reuters
·
Sep 08

Clearmind Medicine Receives Yale Irb Approval, Enabling Patient Recruitment for Parts B and C of Cmnd-100 Phase I/Ii Trial, Following Positive Safety Results

THOMSON REUTERS
·
Sep 08

Clearmind Medicine Agrees to Buy 51% of Charging Robotics for $2.5 Million

Reuters
·
Sep 04

Clearmind Medicine - to Extend $1.50 Mln Loan to Charging Robotics at 4% Interest

THOMSON REUTERS
·
Sep 04